Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina

New England Journal of Medicine

Volumn 333, Issue 12, 1995, Pages 764-769

  Bittl, John A ^a   Strony, John ^b   Brinker, Jeffrey A ^c   Ahmed, Waqar H ^a   Meckel, Clyde R ^a   Chaitman, Bernard R ^d   Maraganore, John ^e   Deutsch, Ezra ^f   Adelman, Burt ^a,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BIOGEN   (United States)

^f TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; HIRULOG;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD VESSEL DIAMETER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RESTENOSIS; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA PECTORIS; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HEPARIN; HIRUDIN THERAPY; HIRUDINS; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; POSTOPERATIVE COMPLICATIONS; RECOMBINANT PROTEINS; SERINE PROTEINASE INHIBITORS;

EID: 0029103184     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199509213331204     Document Type: Article

References (45)

1. Hogg PJ, Jackson CM Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci U S A 1989; 86: 3619-3623
2. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391
3. Eitzman DT, Chi L, Saggin L, Schwartz RS, Lucchesi BR, Fay WP Heparin neutralization by platelet-rich thrombi: role of platelet factor 4. Circulation 1994; 89: 1523-1529
4. Ellis SG, Vandormael MG, Cowley MJ, Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation 1990; 82: 1193-1202
5. Ellis SG, Roubin GS, King SB III, Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988; 77: 372-379
6. Ellis SG, Roubin GS, King SB III, In-hospital cardiac mortality after acute closure after coronary angioplasty: analysis of risk factors from 8,207 procedures. J Am Coll Cardiol 1988; 11: 211-216
7. Detre K, Holubkov R, Kelsey S, Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981: the National Heart, Lung, and Blood Institute Registry. N Engl J Med 1988; 318: 265-270
8. Detre KM, Holmes DR Jr, Holubkov R, Incidence and consequences of periprocedural occlusion: the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990; 82: 739-750
9. Myler RK, Shaw RE, Stertzer SH, Lesion morphology and coronary angioplasty: current experience and analysis. J Am Coll Cardiol 1992; 19: 1641-1652
10. Wolfe MW, Roubin GS, Schweiger M, Length of hospital stay and complications after percutaneous transluminal coronary angioplasty: clinical and procedural predictors. Circulation 1995; 92: 311-319
11. Topol EJ, Bonan R, Jewitt D, Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993; 87: 1622-1629
12. Ambrose JA, Winters SL, Stern A, Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 1985; 5: 609-616
13. Ahmed WH, Bittl JA, Braunwald E Relation between clinical presentation and angiographic findings in unstable angina pectoris, and comparison with that in stable angina. Am J Cardiol 1993; 72: 544-550
14. Gotoh K, Minamino T, Katoh O, The role of intracoronary thrombus in unstable angina: angiographic assessment and thrombolytic therapy during ongoing anginal attacks. Circulation 1988; 77: 526-534
15. Sherman CT, Litvack F, Grundfest W, Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986; 315: 913-919
16. Mizuno K, Satomura K, Miyamoto A, Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326: 287-291
17. Falk E Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985; 71: 699-708
18. Davies MJ, Thomas AC Plaque fissuring -- the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53: 363-373
19. Davies MJ, Thomas AC, Knapman PA, Hangartner JR Intramyocardial platelet aggregation in patients with unstable angina suffering ischemic cardiac death. Circulation 1986; 73: 418-427
20. de Feyter PJ, van den Brand M, Laarman GJ, Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management, and follow-up. Circulation 1991; 83: 927-936 [Erratum, Circulation 1991;84:446.]
21. de Feyter PJ, de Jaegere PPT, Murphy ES, Serruys PW Abrupt coronary artery occlusion during percutaneous transluminal coronary angioplasty. Am Heart J 1992; 123: 1633-1642
22. de Feyter PJ, Serruys PW. Percutaneous transluminal coronary angioplasty for unstable angina. In: Topol EJ, ed. Textbook of interventional cardiology. 2nd ed. Vol. 1. Philadelphia: W.B. Saunders, 1994:274-91.
23. The prognostic importance of the electrocardiogram after myocardial infarction: experience in the Coronary Drug Project. Ann Intern Med 1972; 77: 677-689
24. The TIMI Research Group. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction: TIMI II A results. JAMA 1988; 260: 2849-2858
25. Roubin GS, Cannon AD, Agrawal SK, Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation 1992; 85: 916-927
26. Uehata A, Matsugushi T, Bittl JA, Accuracy of electronic digital calipers compared with quantitative angiography in measuring arterial diameter. Circulation 1993; 88: 1724-1729
27. Rosner B. Regression and correlation methods. In: Rosner B, ed. Fundamentals of biostatistics. 3rd ed. Boston: PWS-Kent, 1990:455-8.
28. Two-sample hypotheses. In: Zar JH. Biostatistical analysis. 2nd ed. Englewood Cliffs, N.J.: Prentice-Hall, 1984:122-49.
29. Ryan TJ, Bauman WB, Kennedy JW, Guidelines for percutaneous transluminal coronary angioplasty: a report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1993; 88: 2987-3007
30. Bittl JA. Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. Am Heart J (in press).
31. Freeman MR, Williams AE, Chisholm RJ, Armstrong PW Intracoronary thrombus and complex morphology in unstable angina: relation to timing of angiography and in-hospital cardiac events. Circulation 1989; 80: 17-23
32. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest: results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation 1993; 87: 38-52
33. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB Trial: thrombolysis in myocardial ischemia Circulation 1994; 89: 1545-1556
34. Bentivoglio LG, Detre K, Yeh W, Williams DO, Kelsey SF, Faxon DP Outcome of percutaneous transluminal coronary angioplasty in subsets of unstable angina pectoris: a report of the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol 1994; 24: 1195-1206
35. Larrazet FS, Dupouy PJ, Rande J-LD, Hirosaka A, Kvasnicka J, Geschwind HJ Angioscopy after laser and balloon coronary angioplasty. J Am Coll Cardiol 1994; 23: 1321-1326
36. Braunwald E, Jones RH, Mark DB, Diagnosing and managing unstable angina. Circulation 1994; 90: 613-622
37. Theroux P, Ouimet H, McCans J, Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-1111
38. Assaf AR, Lapane KL, McKenney JL, Carleton RA Possible influence of the prospective payment system on the assignment of discharge diagnoses for coronary heart disease. N Engl J Med 1993; 329: 931-935
39. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992; 19: 926-935
40. White CJ, Ramee SR, Collins TJ, Jain SP, Escobar A Coronary angioscopy of abrupt occlusion after angioplasty. J Am Coll Cardiol 1995; 25: 1681-1684
41. Sassower MA, Abela GS, Koch JM, Angioscopic evaluation of periprocedural and postprocedural abrupt closure after percutaneous coronary angioplasty. Am Heart J 1993; 126: 444-450
42. Hattersley PG Activated coagulation time of whole blood. JAMA 1966; 196: 436-440
43. Cannon CP, McCabe CH, Henry TD, A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol 1994; 23: 993-1003
44. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961
45. Topol EJ, Califf RM, Weisman HF, Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-886